Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Medicure Inc (2): Medicure receives fast-track designation for MC-1 | 1 | Stockwatch | ||
Di | Medicure, Inc.: Medicure Receives US FDA Fast Track Designation for MC-1 for PNPO Deficiency | 193 | ACCESSWIRE | WINNIPEG, MB / ACCESSWIRE / April 23, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and... ► Artikel lesen | |
09.04. | Medicure GAAP EPS of -$0.09, revenue of $21.7M | 3 | Seeking Alpha | ||
08.04. | Medicure Inc (2): Medicure loses $922,000 in 2023 | 2 | Stockwatch | ||
08.04. | MEDICURE INC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
08.04. | Medicure, Inc.: Medicure Reports Financial Results for Quarter and Year Ended December 31, 2023 | 242 | ACCESSWIRE | WINNIPEG, MB / ACCESSWIRE / April 8, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTCPINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare... ► Artikel lesen | |
05.04. | Medicure Inc (2): Medicure to release 2023 results April 8 | 1 | Stockwatch | ||
05.04. | Medicure, Inc.: Medicure To Present Financial Results on April 9, 2024 Call at 8:30 AM ET for Quarter and Year Ended December 31, 2023 | 279 | ACCESSWIRE | WINNIPEG, MB / ACCESSWIRE / April 4, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and... ► Artikel lesen | |
05.12.23 | Medicure Inc (2): Medicure to distribute Brenzavvy diabetes drug in U.S. | 2 | Stockwatch | ||
05.12.23 | MEDICURE INC - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
05.12.23 | Medicure, Inc.: Medicure Announces New Partnership Through Its Marley Drug Subsidiary to Provide Brenzavvy as an Affordable Medication for Americans with Type 2 Diabetes | 337 | ACCESSWIRE | WINNIPEG, MB / ACCESSWIRE / December 5, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and... ► Artikel lesen | |
23.11.23 | Medicure Inc (2): Medicure gets FDA okay for pediatric drug testing | 2 | Stockwatch | ||
23.11.23 | Medicure, Inc.: Medicure Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease | 412 | ACCESSWIRE | WINNIPEG, MB / ACCESSWIRE / November 23, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals... ► Artikel lesen | |
22.11.23 | MEDICURE INC - 6-K, Report of foreign issuer | - | SEC Filings | ||
21.11.23 | Medicure Inc (2): Medicure earns $84,000 in Q3 | 1 | Stockwatch | ||
21.11.23 | Medicure GAAP EPS of C$0.01, revenue of C$5M | 1 | Seeking Alpha | ||
21.11.23 | Medicure, Inc.: Medicure Reports Financial Results for Quarter Ended September 30, 2023 | 307 | ACCESSWIRE | WINNIPEG, MB / ACCESSWIRE / November 21, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals... ► Artikel lesen | |
30.08.23 | Medicure, Inc.: Medicure Reiterates its Commitment to Providing Exceptional Access to its Branded Pitavastatin to People Living With HIV | 517 | ACCESSWIRE | WINNIPEG, MB / ACCESSWIRE / August 29, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare... ► Artikel lesen | |
29.07.23 | Medicure, Inc.: Medicure Reports Financial Results For Quarter Ended June 30, 2023 | 504 | ACCESSWIRE | WINNIPEG, MB / ACCESSWIRE / July 28, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and... ► Artikel lesen | |
25.07.23 | Medicure, Inc.: Medicure to Present Financial Results on July 31, 2023 Call at 8:30 AM ET for Quarter Ended June 30, 2023 | 461 | ACCESSWIRE | WINNIPEG, MB / ACCESSWIRE / July 24, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PFIZER | 24,565 | -0,14 % | Pfizer - mit Seagan soll die Wende kommen | ||
NOVO NORDISK | 119,28 | +1,39 % | Einmalige Chance? Die Aktien von Eli Lilly und Novo Nordisk haben noch mehr Potenzial als gedacht | Für die Pharmariesen Eli Lilly und Novo Nordisk läuft es schon länger rund. Die aktuellen Blockbuster-Medikamente könnten aber noch erfolgreicher werden als ohnehin schon. Sollten Anleger jetzt noch... ► Artikel lesen | |
GILEAD SCIENCES | 62,93 | +0,50 % | Virushepatitis bis 2030 eliminieren: Gilead Sciences fördert zahlreiche Projekte weltweit mit 4 Millionen US-Dollar - auch in Deutschland | Martinsried bei München (ots) - - Gilead vergibt 4 Millionen US-Dollar weltweit (ohne die Vereinigten Staaten) durch das Förderprogramm "ALL4LIVER Grant" -- Die World Hepatitis Alliance und hochrangige... ► Artikel lesen | |
AURORA CANNABIS | 6,890 | -0,86 % | Kursexplosion bei den Cannabis-Aktien Aurora und Canopy Growth: Jetzt kaufen oder liegen lassen? | Am Donnerstag machten die Cannabis-Aktien von Aurora und Canopy Growth aus einem ganz bestimmten zweistellige Kurssprünge. Sind die Papiere für Anleger jetzt eine Überlegung wert? Mehr als 20 Prozent.... ► Artikel lesen | |
GSK | 19,190 | +1,11 % | Wave Life Sciences USA, Inc.: Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing | GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collaboration; programs utilize Wave's next generation GalNAc-siRNA... ► Artikel lesen | |
ABBVIE | 157,92 | -0,30 % | AbbVie's Phase 3 Study Of Upadacitinib Achieves Primary Endpoint In Giant Cell Arteritis | WASHINGTON (dpa-AFX) - AbbVie Inc. (ABBV) Thursday announced positive results from SELECT-GCA Phase 3 of Upadacitinib 15 mg, once daily in combination with a 26-week steroid taper regimen in... ► Artikel lesen | |
CANOPY GROWTH | 8,380 | -0,71 % | Spotlight on Canopy Growth: Analyzing the Surge in Options Activity | ||
TILRAY BRANDS | 1,717 | -0,41 % | Tilray Aktie: Achterbahnfahrt setzt sich fort | Zum Ende einer bewegten Woche notiert die Aktie des Unternehmens Tilray bei 1.62 €, was einer leichten Veränderung von -0.09% im Vergleich zur Vorwoche entspricht. Die Hoffnungen auf Lockerungen der... ► Artikel lesen | |
ELI LILLY | 696,90 | +0,07 % | Eli Lilly inks deal to acquire Nexus manufacturing plant in WI as Mounjaro and Zepbound shortages drag on | ||
TEVA | 12,000 | -1,64 % | Supreme Court Denies Vanda Pharma' Petition In HETLIOZ Litigation Against Teva, Apotex | PETAH TIKVA (dpa-AFX) - The U.S. Supreme Court denied Vanda Pharmaceuticals Inc.'s (VNDA) petition for a writ of certiorari in its HETLIOZ Abbreviated New Drug Application litigation against... ► Artikel lesen | |
BRISTOL-MYERS SQUIBB | 45,860 | +0,17 % | Biotech im Visier - Bristol-Myers Squibb, Formycon, MorphoSys, Vidac Pharma Aktie | Für viele Pharma- und Biotechaktionäre hat dieser Sektor einen ganz besonderen Charme. In dieser hochspekulativen Branche liegen Erfolg und Misserfolg oft eng beieinander und das führt in der Regel... ► Artikel lesen | |
VERTEX PHARMACEUTICALS | 378,45 | +0,07 % | Vertex Pharma Obtains Exclusive License To TreeFrog's Cell Manufacturing Technology, C-Stem | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX) announced Tuesday that it has obtained an exclusive license from TreeFrog Therapeutics, a French-based biotech company... ► Artikel lesen | |
ABBOTT LABORATORIES | 100,62 | +0,10 % | Abbott Laboratories übertrifft Gewinnerwartungen - Aktie verliert deutlich | ||
TAAT GLOBAL ALTERNATIVES | 0,161 | -8,02 % | TAAT Global Alternatives Inc.: TAAT Announces Shares for Debt Settlement | ||
MPH HEALTH CARE | 20,600 | -2,83 % | EQS-News: MPH Health Care AG verkauft 1,5 Mio. Aktien ihrer Beteiligung M1 Kliniken AG an deren Vorstände | EQS-News: MPH Health Care AG
/ Schlagwort(e): Beteiligung/Unternehmensbeteiligung
MPH Health Care AG verkauft 1,5 Mio. Aktien ihrer Beteiligung M1 Kliniken AG an deren Vorstände... ► Artikel lesen |